CLAIMS:

1. A stable antibody formulation comprising:

   a bispecific anti-IL-4/anti-IL-13 antibody or an antigen binding fragment thereof, comprising a light chain of the formula VL1-linker-VL2 and a heavy chain of the formula VH1-linker-VH2, wherein VL1 and VH1 form an IL-13 antigen binding domain and VL2 and VH2 form an IL-4 antigen binding domain; and

   a buffering system suitable to maintain the pH of the formulation at about pH 7, wherein the buffering system comprises at least two buffers, wherein the buffering system comprises Tris buffer and Phosphate buffer; and

   wherein the formulation comprises mannitol.

2. The formulation of claim 1, wherein

   VL1 comprises the three CDR sequences of SEQ ID NO: 1;

   VH1 comprises the three CDR sequences of SEQ ID NO: 2;

   VL2 comprises the three CDR sequences of SEQ ID NO: 3; and

   VH2 comprises the three CDR sequences of SEQ ID NO: 4 or 5.

3. The formulation of claim 1, wherein

   VL1 comprises the amino acid sequence of SEQ ID NO: 1;

   VH1 comprises the amino acid sequence of SEQ ID NO: 2;

   VL2 comprises the amino acid sequence of SEQ ID NO: 3; and

   VH2 comprises the amino acid sequence of SEQ ID NO: 4 or 5.

4. The formulation of claim 1, wherein the light chain comprises the formula N-VL1-linker-VL2-CL, wherein CL is a light chain constant domain of an antibody, and wherein the heavy chain comprises the formula N-VH1-linker-VH2-CH1-CH2-CH3, wherein CH2-CH3 corresponds to the Fc domain of an antibody.

5. The formulation of claim 1, wherein the linker comprises the amino acid sequence of SEQ ID NO: 6.

6. The formulation of claim 1, wherein the antibody or antigen binding fragment thereof further comprises a constant region domain.

7. The formulation of claim 6, wherein the constant region domain is selected from the group consisting of CH1, CH2, CH3, and CL.

8. The formulation of claim 1, wherein the bispecific antibody or antigen binding fragment thereof is a humanized IgG4 bispecific antibody or antigen binding fragment thereof.

9. The formulation of claim 1, wherein the concentration of antibody or antigen binding fragment thereof is about 100 mg/mL.

10. The formulation of claim 1, wherein the buffering system concentration is about 10 mM.

11. The formulation of claim 1, wherein the Tris buffer concentration is about 3.7 mM.

12. The formulation of claim 1, wherein the Phosphate buffer concentration is about 6.3 mM.

13. The formulation of claim 1, wherein the Tris buffer concentration is about 3.7 mM and the Phosphate buffer concentration is about 6.3 mM.

14. The formulation of claim 1, wherein the formulation further comprises a non-ionic surfactant.

15. The formulation of claim 14, wherein the non-ionic surfactant concentration is about 0.05% to about 0.2% (w/v).

16. The formulation of claim 14, wherein the non-ionic surfactant is a polysorbate.

17. The formulation of claim 16, wherein the polysorbate is polysorbate 80.

18. The formulation of claim 17, wherein the polysorbate 80 concentration is about 0.05% to about 0.2% (w/v).

19. The formulation of claim 18, wherein the polysorbate 80 concentration is about 0.2% (w/v).

20. The formulation of claim 1, wherein the formulation further comprises a sugar.

21. The formulation of claim 20, wherein the sugar concentration is about 5% (w/v).

22. The formulation of claim 20, wherein the sugar is a disaccharide.

23. The formulation of claim 22, wherein the disaccharide is sucrose.

24. The formulation of claim 23, wherein the sucrose concentration is about 5% (w/v).

25. The formulation of claim 1, wherein the mannitol concentration is about 1% to about 3% (w/v).

26. The formulation of claim 1, wherein the mannitol concentration is about 3% (w/v).

27. The formulation of claim 1, wherein the formulation is a lyophilized formulation.

28. The formulation of claim 1, wherein the formulation exhibits stability regarding visible particles, sub-visible particles, low molecular weight proteins, and high molecular weight proteins.

29. A kit comprising a container comprising the formulation of claim 1 and instructions for the administration and use of the formulation.

30. A stable lyophilized antibody formulation comprising:

about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 1 and 3;

about 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer concentration of about 3.7 mM and a Phosphate buffer concentration of about 6.3 mM;

about 0.2% (w/v) polysorbate 80;

about 5% (w/v) sucrose; and

about 3% (w/v) mannitol;

wherein the pH of the formulation is about pH 7.